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Prostate cancer (PCa) preferentially metastasizes to bone result-
ing in osteoblastic lesions with underlying osteolytic activities. The
mechanisms through which PCa cells promote osteolytic activities
and subsequent osteoblastic bone formation remain poorly under-
stood. Parathyroid hormone-related protein (PTHrP), produced
by bone cells and PCa, binds to receptors on osteoblasts and stim-
ulates bone formation and resorption. We have previously
reported that MCP-1 acts as a paracrine and autocrine factor for
PCa progression. However, the role of PTHrP in regulating MCP-
1 expression in bone microenvironment, specifically by human
bone marrow endothelial cells (HBME) and osteoblasts (hFOB),
as well as by PCa cells, has not been studied. Accordingly, we first
determined the effect of PTHrP on MCP-1 expression by bone
cells and PCa cells. PTHrP induced both MCP-1 protein and
mRNA expression by HBME and hFOB cells, but not by PCa
LNCaP and PC3 cells. To further determine the mechanisms of
PTHrP-induced MCP-1 transcription, analysis of the MCP-1 pro-
moter was performed. MCP-1 promoter activity was induced by
PTHrP. Both C/EBPb and NF-jB binding elements are required
for PTHrP-induced MCP-1 transcription. Finally, when a consti-
tutively-active PTH receptor construct was transfected into
HBME and hFOB cells, MCP-1 production was increased. The
conditioned media collected from these cells induced osteoclast
differentiation and PC3 proliferation and invasion in vitro. These
inductions were partially inhibited by MCP-1 neutralizing anti-
body. We conclude that PTHrP-induced MCP-1 production by
HBME and hFOB cells promotes osteoclast differentiation in vitro
and such induction may play a critical role in PCa development in
the bone microenvironment.
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Bone is the most common site of prostate cancer (PCa) metasta-
sis with skeletal metastases occurring in up to 90% of patients
dying from PCa.1,2 Histological studies have revealed that bone
metastatic lesions are a heterogeneous mixture of osteoblastic and
osteolytic lesions, although they are most often radiographically
characterized as predominately osteoblastic responses.3–6 Many
reports have showed that osteoblastic metastases form on trabecu-
lar bone at the sites of previous osteoclastic resorption, and that
such resorption may be required for subsequent osteoblastic bone
formation.2,6 Thus, bone destruction appears to be an early stage
in the development of PCa bone metastasis. However, the mecha-
nisms through which PCa cells promote bone resorption and sub-
sequent osteoblastic bone formation remain poorly understood.
PCa metastasis develops in the skeleton through crosstalk
between tumor cells and bone microenvironment. The bone micro-
environment, which consists of the extracellular matrix, stromal
cells, osteoblasts, osteoclasts, endothelial cells, adipocytes and
hematopoietic cell lineages, produces multiple factors which can
enhance the growth of PCa cells and promote tumor development
in bone. These factors include chemotactic factors, adhesion fac-
tors, growth factors and other inflammatory mediators. Paget pro-
posed the ‘‘seed and soil hypothesis’’ in 1889 to account for the
predilection of metastasis to certain organs [as reviewed in Ref. 7].
Chemokines are classified, based upon the relative position of
cysteine residues near the NH2-terminus, into 4 major families:
CC, CXC, C and CX3C. In addition to their roles in chemotaxis,
one important role for chemokines in tumor biology that has been
suggested is that they may regulate the metastatic behavior of tu-
mor cells. For example, the CXC chemokine, stromal-derived fac-
tor (SDF-1/CXCL12) and its receptor CXCR4, are responsible for
hematopoietic stem cell homing to the marrow and has also been
implicated in the pathogenesis of PCa bone metastasis.8,9 Tumor
cells that frequently metastasize to bone (myeloma, breast cancer,
PCa and neuroblastoma) all express CXCR4.10–15 However,
blocking CXCR4 only partially inhibits bone metastasis.11,16
These results suggest that other factors produced by tumors and/or
cells in the bone microenvironment can attract and stimulate the
tumor growth.
MCP-1, a member of the CC chemokine superfamily, plays a
critical role in the recruitment and activation of monocytes during
acute inflammation and angiogenesis. In vitro studies have shown
that for most normal cell types there is little or no MCP-1 expres-
sion and exogenous stimulation is required for the induction of
MCP-1.17 However, a variety of cancer cells that home to bone,
including PCa, breast cancer and myeloma cells, express MCP-1
and its receptor CCR2.18–20 We have recently demonstrated that
MCP-1 is chemotactic for PCa cells.18 In addition, MCP-1 is pro-
duced by bone cells such as human bone marrow endothelial
(HBME) cells,21 osteoblasts22,23 and osteoclasts.24–27 Both recep-
tor activator of NF-jB ligand (RANKL) and Tumor necrosis fac-
tor-a (TNF-a) modulate MCP-1 expression in osteoclasts.24–27
Thus, MCP-1 appears to play a role in tumor progression in bone.
Parathyroid hormone-related protein (PTHrP), a 141-amino
acid protein that has limited homology to PTH, binds the same re-
ceptor as PTH with similar biological activity.28,29 It acts as an
autocrine and paracrine factor on osteoblasts and modulates bone
formation and resorption.28,30 Furthermore, PTHrP is highly
expressed on metastatic bone lesions31 compared to a moderate
expression on localized PCa tissues32,33 and cell lines.34 PTHrP
has been shown to enhance bone metastases in animal models of
PCa35 and breast cancer.36–39 However, how PTHrP promotes the
tumor-associated osteolysis is not clear. In this study, we investi-
gated the role of PTHrP in MCP-1 production in the bone micro-
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environment, specifically by bone HBME cells and osteoblasts, as
well as by PCa cells.
Material and methods
Antibodies and reagents
Rabbit polyclonal antibodies against human PTH receptor
(PTHR) and GAPDH, mouse monoclonal antibodies against
human C/EBPb and NFjB (p65), C/EBPb siRNA, NFjB (p65)
siRNA and control siRNA (scrambled siRNA) were purchased
from Santa Cruz Biotechnology (Santa Cruz, CA). Murine MCP-1
neutralizing antibody, isotype IgG control antibody, recombinant
human MCP-1 (rhMCP-1), recombinant murine M-CSF (M-CSF),
and recombinant murine RANKL (rmRANKL), were purchased
from R & D Systems (Minneapolis, MN). Human PTHrP(1–34)
were obtained from Bachem (Torrance, CA). All other chemical
reagents were purchased from Sigma (St. Louis, MO).
Cell culture
HBME, hFOB (SV 40 large T antigen transfected and immor-
talized human osteoblasts), human PCa cell lines LNCaP and PC3
were obtained from American Type Tissue Collection (ATCC,
Rockville, MD). HBME cells were cultured in DMEM media.
Human FOB cells were grown in media with 50% DMEM and
50% Ham’s F12 (Invitrogen) at 34C. At this temperature, the
cells exhibit rapid cell division since this cell line was established
by transfection of a temperature sensitive expression vector
pUCSVtsA58. LNCaP and PC3 cells were cultured in RPMI 1640
media (Invitrogen, Carlsbad, CA). All the media were supple-
mented with 10% fetal bovine serum (FBS), 100 units/ml penicil-
lin and 100 lg/ml streptomycin. HBME, LNCaP and PC3 cells
were maintained in 100-mm tissue culture dishes in a 37C incu-
bator equilibrated with 5% CO2 in humidified air.
ELISA
HBME, hFOB, LNCaP and PC3 cells were plated in their main-
tenance media into 6-well-plates at 3 3 105/well in triplicates.
Cells were grown for 12 hr, and then the media was changed to
serum-free media. In one experiment, the cells were treated with
either vehicle, or 1028 M PTHrP or 20 ng/ml TNFa for 6 hr or
24 hr. In another experiment, the HBME and hFOB cells were
treated with 1028 M PTHrP for 6 hr, then exposed to either vehi-
cle, or cycloheximide (10 ug/ml) for 0, 1 or 2 hr. The supernatant
was collected and MCP-1 level was measured by ELISA. Quanti-
kine Human MCP-1 ELISA kits were purchased from R & D Sys-
tems. ELISAs were performed according to the manufacturer’s
instructions.
Quantification of PTHR and MCP-1 mRNA expression by
real-time RT-PCR
Total RNA was extracted from nontreated HBME, hFOB,
LNCaP and PC3 cells and the cells treated as earlier. Total RNA
was extracted using TRIzol reagent (Life Technologies, Gaithers-
burg, MD), then subjected to real-time RT-PCR in an iCycler iQ
multicolor real-time PCR detection system (Bio-Rad, Hercules,
CA) using the iScript one-step RT-PCR kit with SYBR Green
(Bio-Rad). Melting curve analysis was performed to confirm the
purity of the PCR products. Duplicate samples were run for each
primer set. The relative expression of PTHR to GAPDH and
MCP-1 to GAPDH (as housekeeping gene control) was calculated.
Primers for PTHR consisted of sense 50-ACC AAT GAG ACT
CGT GAA CGG-30, and antisense 50-AAG GAC AGG AAC AGG
TGC ATG-30. MCP-1 primers were: sense 50-TCG CGA GCT
ATA GAA GAA TCA-30 and antisense 50-TGT TCA AGT CTT
CGG AGT TTG-3. GAPDH primers were: sense 50-CCA TGG
AGA AGG CTG GGG-30 and antisense 50-CAA AGT TGT CAT
GGA TGA CC-30.
Reverse transcription-PCR
Total RNA from HBME, hFOB, LNCaP and PC3 cells was
extracted. RT-PCR was performed with 1lg of total RNA using
the Access RT-PCR system (Promega Corp., Madsion, WI) in a
thermal cycler (GeneAmp PCR System 2700, Applied Biosys-
tems, CA) under the following conditions: first strand cDNA was
synthesized at 48C for 45 min; then denatured at 94C for 2 min
for the first cycle and at 30 sec for additional 35 cycles; annealing
was performed at 55C for 30 sec and extension at 72C for
60 sec. Final extension was at 72C for 7 min. The PCR products
were subjected to electrophoresis on a 1.5% agarose gel and
stained with ethidium bromide. RT-PCR primers for PTH receptor
consisted of sense 50-ACC AAT GAG ACT CGT GAA CGG-30,
and antisense 50-AAG GAC AGG AAC AGG TGC ATG-30,
resulting in a PCR product of 167 bp. GAPDH primers were:
sense 50-CCA TGG AGA AGG CTG GGG-30 and antisense 50-
CAA AGT TGT CAT GGA TGA CC-30, resulting in a PCR prod-
uct of 194 bp.
Western blot analysis
Cell lysates from HBME, hFOB, LNCaP, PC3 cells and HBME
and hFOB cells transfected with PTHR (H223R) were prepared
using standard procedures. All the samples were measured for
total protein content using a BCA assay (Pierce, Rockford, IL) to
ensure equal loading. Loading buffer was added to 40 lg protein
and samples were boiled prior to being resolved on 12% SDS-
PAGE gels and then transferred onto PVDF membranes (Bio-
Rad). The blots were blocked using blocking reagents overnight at
4C with shaking and then incubated for 2 hr with primary anti-
body for PTHR (diluted 1:200 in blocking solution). The blots
were washed and incubated for 1 hr with goat antirabbit IgG-HRP
(1:3,000). After washing, bands were detected using enhanced
chemiluminescence (Amersham Biosciences, Piscataway, NJ) and
exposed to light-sensitive film. As control for equal loading of the
proteins, immunoblots for GAPDH (Santa Cruz, CA) were per-
formed on the stripped membranes. PTHR was normalized to
GAPDH, and the relative change was calculated using the mean
value of changes from 3 replicates. Cell lysates from HBME cells
transfected with C/EBPb siRNA, NFkB p65 siRNA or control
siRNA were used to determine C/EBPb and NFkB p65 protein
expression using the same protocol.
Effects of actinomycin D on MCP-1 expression in HBME cells
HBME cells were plated into 6-well-plates at 3 3 105/well.
HBME Cells were treated with either vehicle or 1028 M PTHrP
for 6 hr and then exposed to either the vehicle or actinomycin D
(1 lg/ml) for 0, 1 or 2 hr. Total RNA was collected and MCP-1
mRNA expression was determined by real-time RT-PCR.
Transfection and MCP-1 promoter activity measurement
Reporter vectors pGL3-MCP1 (MCP1-3.6kb/Luc), MCP1-C/
EBPMAB/Luc, which has mutated C/EBP binding sites, and
MCP1-NFjBMAB/Luc, which has mutated NF-jB binding sites,
were constructed and used as described previously.40 HBME or
hFOB cells were grown to 80% confluence in T75 flasks, try-
psinized, washed in PBS, and replated at 3 3 104 cells/well in
24-well culture plate in maintaining media. Twelve hours after
plating, cells were cotransfected with pGL3-MCP1, MCP1-C/
EBPMAB/Luc, MCP1-NFjBMAB/Luc, PGL-3 basic (empty vec-
tor) and promoter-linked Renilla luciferase vector, pRL-TK
(Promega Corp) as a normalization reference for transfection effi-
ciency using FuGENE 6 Transfection Reagent (Roche Diagnostic
Corp., Indianapolis, IN). Twenty-four hours after the transient
transfection, medium was changed to DMEM with 0.5% charcoal-
stripped FBS, and cells were then treated with either vehicle or
1028 M PTHrP, 20 ng/ml TNFa for 24 hr. The cells were lysed
with lysis buffer (Promega Corp) and the luciferase activity was
quantified using a microplate luminometer (Turner Biosystems,
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Sunnyvale, CA) using the protocol from Dual-Luciferase Reporter
assay system (Promega Corp).
siRNA knock down experiment
The designed C/EBPb siRNA, NFjB P65 siRNA, or scrambled
siRNA were transfected into HBME cells using the transfection
reagents from Santa Cruz. In brief, HBME cells were cultured in
6-well plates (3 3 105/well) with antibiotic-free cell growth
medium 1 day prior to transfection. For each transfection, 1 lg of
siRNA duplex was diluted in siRNA transfection medium to a
final volume of 100 ll. Six microliter siRNA transfection reagent
was diluted into 100 ll siRNA transfection medium and added
directly into the siRNA duplex solution. After 30 min incubation
at room temperature, 0.8 ml transfection medium was added to
each tube containing the siRNA and transfection reagent mixture,
then overlayed the mixture onto the cells which had been washed
by siRNA transfection medium. Cells were incubated for 6 hr at
37C and cell growth media containing 23 serum and antibiotics
were then added. The cells were incubated for an additional 24 hr
and the media was replaced with cell growth media with charcoal-
stripped FBS plus 1028 M PTHrP, and continued to culture for 24 hr.
Cell lysates were collected forWestern blot and the cell culture super-
natants were collected forMCP-1 ELISAmeasurement.
PTH receptor transfection into HBME and hFOB cells and
obtaining CM
Transient transfection was performed in 35-mm tissue culture
dishes (HBME and hFOB cells at 2 3 105) using a constitutively
active PTH receptor (H223R) or empty vector constructs (kindly
provided by Dr. E. Schipani, Department of Medicine, Massachu-
setts General Hospital and Harvard Medical School). Briefly,
HBME or hFOB cells were co-transfected, using FuGENE 6
(Roche Diagnostic Corp.) reagents, with either PTH receptor
(H223R) or empty vector plus b-gal expression vector as an inter-
nal control for normalization of transfection efficiency. Twenty-
four hours after transfection, medium was changed to DMEM
with 0.5% charcoal-stripped FBS with either vehicle or H89
(10 lM), a protein kinase A inhibitor. After 48 hr, the CM was
collected and MCP-1 production was measured by ELISA. The
CM was used in osteoclast formation assays as described later. To
normalize for differences in cell density because of proliferation
during the culture period, cells from each plate were collected and
the total DNA content/plate was determined (spectrophotometric
absorbance, 260 nm). The CM was then normalized for DNA con-
tent between samples by adding DMEM.
Osteoclast formation assay
Primary mouse bone marrow cells were obtained by flushing
femora from 4–6 weeks old C57BL/6 mice. The animal protocol
was approved by the Institutional Animal Care and Use Commit-
tee, University of Pittsburgh. Briefly, the bone marrow cells were
incubated in a-MEM with 20% FBS overnight at 37C in 100-mm
tissue culture plates to separate nonadherent and adherent cells.
Osteoclast formation assays were performed by culturing 1 3 105/
well nonadherent cells in 96-well plates in 0.1 ml of a-MEM with
20% FBS for 7 days. The cells were incubated with rmM-CSF (10
ng/ml) and/or rmRANKL (50 ng/ml) and 10% CM collected from
the HBME or hFOB PTH receptor-transfected cells in the pres-
ence of various doses of antimouse MCP-1 neutralizing antibody
or isotype control antibody. In each case, half of the media was
changed at day 4. After 7 days of culture, the cells were fixed with
2% formaldehyde and stained with K-ASSAY TRAP staining kit
(Kamiya Biomedical, Seattle, WA). Using an inverted micro-
scope, the positive staining cells that contained 3 or more nuclei
were counted as osteoclast-like cells. Analysis of all osteoclast
formation experiments included data from 3 independent experi-
ments.
PCa cell proliferation
Cell proliferation was measured using a CellTiter 96 AQeous
Nonradioactive cell proliferation assay (Promega, Madison, WI).
Briefly, PC3 cells were plated in 96-well plates at a density of
2,000 cells/well, in 200 ll of RPMI 1640 plus 0.5% FBS. CM
(10%) collected from PTHR (H223R) with either MCP-1 neutralizing
FIGURE 1 – PTH receptors are expressed on HBME, hFOB, LNCaP and PC3 cells. Total RNA and cell lysates were extracted from HBME,
hFOB, LNCaP and PC3 cells. (a) PTHR mRNA expression was determined by RT-PCR. The PCR products were subjected to electrophoresis
on a 1.5% agarose gel, stained with ethidium bromide. (b) Relative PTHR mRNA expression was determined by Real-time RT-PCR. Data is
representative of 3 separate experiments and is presented as mean 6 SE from triplicates. (c) PTHR protein expression was determined by
Western blot. (d) Quantitive data for Western blot. The data is representative of 2 separate experiments and is presented as mean 6 SE from
replicates.
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antibody (1lg/ml) or control IgG (1 lg/ml) was added into the
cultures. The cells were incubated at 37C in a humidified 5%
CO2 atmosphere for 24, 48, 72 hr, then 20 ll of combined MTS/
PMS solution was added. After incubation for 2 hr at 37C, the ab-
sorbance of each well at 490 nm was recorded by using an ELISA
plate reader. Data represent the average absorbance of 4 wells.
In vitro PCa cell invasion assay
The invasiveness of PC3 cells was evaluated in 24-well matrigel
invasion chamber (BD Biosciences, Bedford, MA), as previously
described.18 Briefly, to assess the ability of the PC3 cells to pene-
trate the matrigel, PC3 cells (2.53 104/well) were placed in 0.5 ml
of RPMI medium containing 5% FBS in the upper compartment of
FIGURE 2 – PTHrP induced MCP-1 expression by HBME and hFOB cells, but not by PCa cells. (a,c,e,f) HBME, hFOB and (b,d) LNCaP,
PC3. Cells (3 3 105/well) were plated in a 6-well plate in cell culture media plus 10% FBS for 12 hr, and then the media was changed to serum-
free DMEM media. For (a,b,c,d), the cells were treated with either vehicle, or 1028 M PTHrP or 20 ng/ml TNFa (as a positive control) for 6 hr
or 24 hr. For (e), the cells were treated with indicated concentration of PTHrP for 6 hr. For (f), the cells were treated with 1028 M PTHrP for
6 hr, and then exposed to either vehicle or actinomycin D (1 ug/ml) for 0, 1 or 2 hr. (a,b). The supernatants were collected and MCP-1 levels
were measured by ELISA. Data are presented as mean 6 SD from triplicates. Data is a representative of 2 separate experiments. *p < 0.001
compared to the vehicle-treated cells. (c,d,e,f). Total RNA was extracted from the cells, and then subjected to real-time RT-PCR using appropri-
ate primers. GAPDH was served as an internal control. MCP-1 mRNA expression was calculated relative to the expression of GAPDH. Data is
representative of 3 separate experiments and is presented as mean6 SE from triplicates. *p < 0.001 compared to the vehicle-treated cells.
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wells that were precoated with the reconstituted matrix and 0.75 ml
of RPMI medium containing 10% FBS in the lower compartment.
In the lower compartments, CM (10%) collected from PTHR
(H223R) with either MCP-1 neutralizing antibody (1 lg/ml) or con-
trol IgG (1 lg/ml) was added. The transwell chambers were incu-
bated for 24 hr at 37C in 95% air and 5% CO2. Cell penetration
through the membrane was detected by staining the cells on the po-
rous membrane with a Diff-Quik stain kit (Dade Behring, Newark,
DE) and quantified by counting the numbers of cells that penetrated
the membrane in 5 microscopic fields (at 2003 magnification) per
filter. Invasive ability was defined as the proportion of cells that
penetrated the matrix-coated membrane divided by the number of
cells that migrated through the uncoated membrane (baseline
migration). The results are reported from triplicate assays.
Statistical analysis
Statistical significance was determined for multivariate compar-
isons using ANOVA and Fisher’s probable least significant differ-
ence for post hoc analysis. Student’s t test was used for bivariate
analyses. Statistical significance was determined as p < 0.05.
Statistical calculations were performed using Statview software
(Abacus Concepts, Berkeley, CA).
Results
PTH receptor expression on HBME, hFOB, LNCaP and PC3 cells
PTHrP functions through binding to its receptors on the target
cells. Therefore, we determined if the HBME, hFOB, LNCaP and
PC3 cells express the PTH receptor and, thereby, could respond to
PTHrP. We found that HBME, hFOB, LNCaP and PC3 cells
express both PTH receptor mRNA and protein as identified by
RT-PCR and western blot, repectively, (Figs. 1a and 1c) indicat-
ing that these cells are capable of responding to PTHrP. There are
no significant differences on PTHR expression levels among these
cells (Figs. 1b and 1d).
Effect of PTHrP on MCP-1 production by the both bone cells
and PCa cells
To determine whether PTHrP influences MCP-1 expression by
bone cells such as HBME and hFOB, as well as by PCa epithelial
cells, HBME, hFOB, LNCaP and PC3 cells were treated with
either vehicle, or 1028 M PTHrP, or 20 ng/ml TNFa (as a positive
control) for 6 hr or 24 hr. The conditioned media were collected
and MCP-1 levels were measured by ELISA. PTHrP significantly
induced MCP-1 production by HBME cells, particularly at 24 hr
FIGURE 3 – PTHrP induced MCP-1 promoter activity is dependent on the NFjB and C/EBPb binding elements. (a) HBME and hFOB cells
(3 3 104/well) were plated in a 24-well plate and transiently cotransfected with PGL3-MCP-1 and pRL-TK plasmids. Twenty-four hours after
the transient transfection, the cells were treated with either vehicle, or increasing doses of PTHrP. (b) HBME cells were transiently cotransfected
with luciferase expression plasmids (PGL3-MCP-1, MCP-1-NFjBMAB, MCP-1-C/EBPMAB or PGL3-Basic) and pRL-TK plasmid. Twenty-
four hours after the transient transfection, the cells were treated with either vehicle, or 1028 M PTHrP, 20 ng/ml TNFa for 24 hr. Luciferase
activities were measured by dual-luciferase reporter assay system (Promega). Results are expressed as mean 6 S.E. of relative luciferase activ-
ities. Results are from 3 independent experiments, and each observation was performed in duplicate. *p < 0.001 compared to the vehicle-treated
cells. (c,d) The designed C/EBPb siRNA, NFjB P65 siRNA, or scrambled siRNA were transfected into HBME cells using the transfection
reagents. The cells were treated with 1028 M PTHrP for 24 hr. Cell lysates were collected for Western blot and the cell culture supernatants
were collected for MCP-1 ELISA measurement. Data are presented as mean 6 SD from triplicates. Data is a representative of 2 separate experi-
ments. *p < 0.001 compared to the control siRNA-transfected cells.
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(Fig. 2a). It also, less potently, induced MCP-1 production by
hFOB cells. However, PTHrP was not observed to induce either
MCP-1 protein production (Fig. 2b) or MCP-1 mRNA production
(Fig. 2d) by the 2 PCa cell lines, LNCaP and PC3. After 24-hr
PTHrP treatment, the MCP-1 level in the CM from PTHrP-treated
HBME and hFOB cells increased 4.1-fold and 2.8-fold, respec-
tively, as compared to the CM from vehicle-treated cells (Fig. 2a).
To determine whether this PTHrP-induced MCP-1 protein induc-
tion is due to increased MCP-1 mRNA transcription, total RNA
from these cells was collected and MCP-1 mRNA expression was
quantified by real-time RT-PCR. Consistent with the observed
PTHrP induction of MCP-1 protein production, PTHrP also signif-
icantly induced MCP-1 mRNA expression by HBME cells (8.7-
fold at 6 hr and 6.9-fold at 24 hr) and hFOB cells (4.1-fold at 6 hr
and 3.1-fold at 24 hr) (Fig. 2c). Time course analyses for PTHrP
(1028 M) induction of MCP-1 mRNA and protein showed that
while the peak steady-state MCP-1 mRNA is at 2 hr (Fig. 2c and
data not shown), the peak protein accumulation is at 24 hr in both
HBME and hFOB cells (Fig. 2a). PTHrP induces MCP-1 mRNA
expression in a dose-dependent manner (Fig. 2e). To determine
whether the PTHrP-induced MCP-1 mRNA expression may
require active mRNA syntheses, we tested the PTHrP-induced (6
hr treatment) and the steady state of MCP-1 mRNA expression in
HBME cells after treatment with actinomycin D, an inhibitor of
RNA synthesis. PTHrP-induced MCP-1 mRNA expression was
significantly diminished within 1–2 hr by the addition of actino-
mycin D to the cell cultures (Fig. 2f). The cells treated with actino-
mycin D for 1–2 hr did not change the steady state of MCP-1
mRNA expression in HBME cells (not shown). Consistent with
the mRNA findings, we also observed that cycloheximide (10 lg/
ml), a protein synthesis inhibitor, diminishes the PTHrP-induced,
but not the steady state of MCP-1 protein expression within 1–2 hr
treatment determined by ELISA (not shown).
Effect of PTHrP on MCP-1 transcription in bone cells
To further determine the mechanisms of PTHrP-induced MCP-
1 transcription in HBME and hFOB cells, a construct containing
the full length MCP-1 promoter driving luciferase was transiently
transfected into HBME and hFOB cells. PTHrP dose-dependently
increased the MCP-1 promoter-driven luciferase activity in both
cells (Fig. 3a). To identify the cis-elements important for the
MCP-1 promoter response to PTHrP treatment, we used 2 mutant
constructs to evaluate the contribution of C/EBP and NF-jB bind-
ing sites: MCP1-C/EBPMAB/Luc, which has mutated C/EBP
binding sites; and MCP1-NFjBMAB/Luc, which has mutated
NF-jB binding sites. PTHrP failed to induce both MCP1-C/EBP-
MAB/Luc and MCP1-NFjBMAB/Luc, suggesting that both
elements are required for PTHrP-induced MCP-1 transcription in
HBME cells (Fig. 3b). In contrast, TNFa induced MCP1-
NFjBMAB/Luc promoter activity but not MCP1-C/EBPMAB/
Luc promoter activity, indicating that TNFa and PTHrP may
induce MCP-1 through different transcription factors. In addition,
we observed similar results for MCP-1 transcriptional regulation
by PTHrP in hFOB cells (data not shown). To further provide evi-
dence for the role of transcriptional factors C/EBP and NF-jB in
PTHrP-induced MCP-1 production, using HBME cells as an
example, either C/EBP or NF-jB siRNA were transfected into
HBME cells followed by PTHrP treatment. Both C/EBP and NF-
jB siRNA significantly dimished MCP-1 production (Figs. 3c and
3d). When either C/EBP and NF-jB siRNA were transfected into
LNCaP or PC3 cellls followed by PTHrP treatment, the MCP-1
production by these cells were not altered indicating that the tran-
scriptional factors such as C/EBP and NF-jB may not be induced
by PTHrP in this condition (data not shown).
Effect of PTHrP-induced MCP-1 production on osteoclast
differentiation in vitro
Using HBME and hFOB cells as examples, we determined the
function of this PTHrP-induced MCP-1 production in bone cells.
First, a constitutively-active PTH receptor construct (H223R) was
transiently transfected into both HBME and hFOB cells (Fig. 4a).
Twenty-four hours after transfection, medium was changed to
DMEM with 0.5% charcoal-stripped FBS with vehicle or H89, a
PKA inhibitor. After 48 hr, we collected the CM and measured
MCP-1 levels in the CM by ELISA. MCP-1 protein production by
both HBME and hFOB cells was significantly increased by trans-
fection with PTHR (H223R) compared to the vector (Fig. 4b). As
PTHR/cAMP-PKA is one of the major cascades in PTHR func-
tion, H89 was incorporated into this study. As expected, H89 sig-
nificantly diminished MCP-1 induction by both cells (Fig. 4b).
The CM from the HBME was then utilized for an in vitro osteo-
clast differentiation assay using murine bone marrow nonadherent
cells. The CM (10%) induced osteoclast differentiation in vitro
and this induction was dose-dependently inhibited by adding
MCP-1 neutralizing antibody, whereas the isotype control anti-
body did not inhibit (Figs. 5a and 5b). The highest concentration
(1 lg/ml) of neutralizing antibody only partially inhibited the CM-
induced osteoclast differentiation. We observed similar results
using hFOB cells (data not shown).
Effect of CM collected from PTHR (H223R) HBME cells on PC3
cell proliferation and invasion
We have previously reported that MCP-1 induces PCa cell pro-
liferation and invasion in vitro.18 To further determine whether
the CM collected from PTHR (H223R)-transfected HBME cells
may, through MCP-1, induce PCa cell proliferation and invasion,
PC3 cells were treated with either neutralizing antibody for MCP-
1 or control IgG in the presence of CM (10%) collected from
PTHR (H223R) HBME cells. The neutralizing MCP-1 antibody
significantly diminished both PC3 cell proliferation (Fig. 6a) and
invasion (Fig. 6b) induced by the CM.
Discussion
Bone is the most frequent site for distant metastasis from PCa.
The skeletal lesions form due to the interaction between tumor
cells and the bone microenvironment. Chemokines, cytokines,
growth factors and other inflammatory mediators produced in the
bone microenvironment modulate activity of osteoblasts and
osteoclasts. One factor that can be produced by both bone and PCa
cells is PTHrP. In the present study, we found that PTHrP induces
FIGURE 4 – MCP-1 levels in CM from HBME and hFOB cells
expressing a constitutively-active PTH receptor. HBME and hFOB cells
were transiently cotransfected with either a constitutively-active PTH
receptor (H223R) construct or empty vector plus b-gal expression vec-
tor as an internal control for normalization of transfection efficiency.
(a) PTHR protein expression was determined by Western blot. EV rep-
resents empty vector. (b) CM was collected as described in Materials
and methods. MCP-1 levels were measured by ELISA. Data are pre-
sented as mean 6 SD from triplicates. *p < 0.001 compared to vector-
transfected CM. p < 0.001 compared to the vehicle-treated CM.
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MCP-1 expression, at both the mRNA and protein levels, by
HBME and hFOB cells (Figs 2a, 2c and 2e). However, although
the 2 PCa cell lines, LNCaP and PC3, express the PTH receptor
(Fig. 1), PTHrP induces neither MCP-1 protein production nor
mRNA expression in these cells (Figs. 2b and 2d). We also found
that PTHrP-induced MCP-1 mRNA expression requires active
gene transcription because PTHrP-induced MCP-1 mRNA expres-
sion can be significantly inhibited by actinomycin D (Fig. 2f). To
our knowledge, this is the first report that shows that PTHrP can
induce MCP-1 production by HBME and hFOB cells, and thus
play an important role in PCa growth in bone. Of interest, RANKL
protein levels were measured by ELISA in the HBME and hFOB
cells treated with PTHrP for 24 hr. We observed less than 15 and
11% induction (less potent than MCP-1 induction) in HBME and
hFOB cells, respectively (data not shown), suggesting MCP-1
expression is significantly induced by PTHrP in these cells.
Furthermore, we have begun to characterize the transcriptional
regulation of MCP-1 by PTHrP. PTHrP was found to induce
FIGURE 5 – Induction of osteoclast differentiation by PTHrP-induced MCP-1 production in vitro. Nonadherent MBMCs were cultured at 1 3
105/well in 96-well plates for 7 days. The cells were incubated with rmM-CSF (10 ng/ml) and/or rmRANKL (50 ng/ml) or 10% CM collected
from either vector- or PTHR (H223R)-transfected cells in the presence of various doses (0.01–1 lg/ml) of MCP-1 neutralizing antibody. After 7
days, the cells were fixed and murine osteoclast-like cells were identified by TRAP staining. (a) Representative pictures of TRAP staining. (b)
Number of osteoclast-like multinucleated cells per well were quantified. Samples were evaluated in quadruplicate. Results are reported as mean
6 SD. Data were analyzed using one-way ANOVA. *p < 0.001 compared to the CM collected from vector-transfected cells; **p < 0.005 com-
pared to the CM collected from PTHR (H223R)-transfected cells; p < 0.01 compared to the CM collected from vector-transfected cells; #p <
0.001 compared to the MCP-1-treated cells.
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MCP-1 promoter activity in HBME and hFOB cells. In accordance
with the fact that binding of NF-jB is important for human MCP-1
transcription in human glioblastoma,41 monocytes,42 rat kidney tu-
bular epithelial cells43 and vascular smooth muscle cells,44 we
observed that the NFjB binding elements are required for PTHrP-
induced MCP-1 promoter activity in HBME and hFOB cells
because mutation of the 2 NFjB binding sites leads to the loss of
PTHrP-stimulated promoter activity (Fig. 3). Similarly, the C/
EBPb binding elements were also demonstrated to be necessary for
MCP-1 promoter activation stimulated by PTHrP. The latter finding
is consistent with reports that the C/EBP elements are essential for
induction of MCP-1 gene expression by lipopolysaccharide in a
lymphoblastic cell line45 and by nitric oxide in vascular smooth
muscle cells.46 As Sp1 binding is critical for MCP-1 promoter as-
sembly and activation by TNFa,47 Sp1 response elements and other
cis-elements including AP-1 response elements that may be impor-
tant for the response to PTHrP need to be further characterized.
Interestingly, TNFa induced MCP-1 expression in HBME and
hFOB cells, but the induction of MCP-1 promoter activity was
through the C/EBP elements and not the NF-jB elements. This is
consistent with the lack of a requirement for these sites for TNFa
induction of the MCP-1 promoter in leiomyosarcoma (SKLMS1)
cells, and in contrast to the requirement for these NF-kB elements
in order for TNFa to induce the MCP-1 promoter in fibrosarcoma
(HT1080) and glioblastoma (A172) cells.42 Therefore, MCP-1 tran-
scription regulation appears tissue-specific and stimulus-specific.
Finally, the significance of the PTHrP-induced MCP-1 produc-
tion by HBME and hFOB cells was examined by assessing its role
in osteoclast differentiation in vitro. To test this, a constitutively-
active PTH receptor was first transfected into HBME and hFOB
cells (Fig. 4). The CM collected from these cells was tested for its
capacity to induce osteoclast differentiation in vitro using primary
murine nonadherent bone marrow cells. We observed that the CM
from cells with the activated PTH receptor induced osteoclast dif-
ferentiation in vitro and that this induction was dose-dependently
inhibited by adding MCP-1 neutralizing antibody (Fig. 5). Inter-
estingly, the high concentration of neutralizing antibody only par-
tially inhibited the CM-induced osteoclast differentiation suggest-
ing that the activated PTH receptor in HBME stimulated the pro-
duction of other factors that were secreted into the CM that may
also induce osteoclast differentiation.
Although chemokines were first described based upon their
capacity to stimulate recruitment and activation of leukocytes, it
has become evident that they possess other functions including
regulating events in bone marrow. It was reported that MCP-1 is
induced by RANKL and it promotes osteoclast fusion and rescues
granulocyte macrophage colony-stimulating factor suppression of
osteoclast formation.48 In the current study, the PTHrP-induced
MCP-1 production resulted in formation of multinucleated cells in
the absence of RANKL suggesting that MCP-1 is sufficient for
osteoclast fusion events. This result is consistence with a recent
report that MCP-1-induced TRAP positive multinuclear cells rep-
resent an arrested stage in osteoclast differentiation.49
In this study, we further demonstrated that CM collected from
PTHR (H223R)-transfected HBME cells, through MCP-1, induce
PC3 cell proliferation and invasion since the MCP-1 neutralizing
antibody inhibited the CM-induced PC3 proliferation and invasion
(Fig. 6). Together with the recent findings that humanized mono-
clonal antibody against PTHrP suppresses osteolytic bone metas-
tases of breast cancer cells,50 we postulate that PTHrP-induced
MCP-1 production in the bone microenvironment, specifically by
HBME and hFOB cells, may enhance osteoclast differentiation
that results in osteolysis. The tumor-associated osteolysis may
cause the release of bone matrix-associated factors such as trans-
forming growth factor-b and insulin growth factors, and these
factors may increase bone formation through stimulation of osteo-
blasts and contribute to osteoblastic lesions of PCa bone metasta-
sis. In conclusion, we observed that PTHrP-induced MCP-1 pro-
duction by HBME and hFOB cells promotes osteoclast differentia-
tion and PC3 proliferation and invasion in vitro. This newly
characterized function of PTHrP may play a critical role in PCa
skeletal metastasis.
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